Variable | PsA (N=203) | PsC (N=155) | p Value |
---|---|---|---|
Age (years), mean±SD | 51.6 (13) | 50.3 (12.4) | 0.33 |
Sex: female | 80 (39.4%) | 68 (43.9%) | 0.39 |
Age at onset of psoriasis (years), mean±SD | 26.5 (13.1) | 30.7 (16.9) | 0.01 |
Age at onset of PsA (years), mean±SD | 37 (12.8) | ||
Ethnicity: Caucasian | 176 (87.1%) | 128 (82.6%) | 0.23 |
Alcohol consumption: daily | 15 (7.4%) | 20 (12.9%) | 0.001 |
Social | 95 (46.8%) | 89 (57.4%) | |
Smoker: current | 23 (11.3%) | 31 (20%) | 0.06 |
Past smoker | 51 (25.1%) | 46 (29.7%) | |
Active joint count, mean±SD | 4.6 (7.8) | ||
Damaged joint count, mean±SD | 7.6 (12.3) | ||
PASI, current, mean±SD | 3.6 (5.5) | 5.3 (5.3) | 0.003 |
SBP (mm Hg), mean±SD | 124 (16.9) | 120 (16.5) | 0.07 |
DBP (mm Hg), mean±SD | 77.8 (8.9) | 77.4 (9.6) | 0.75 |
Anti-hypertensive medications | 65 (32%) | 33 (21.9%) | 0.02 |
Hypertension | 119 (58.6%) | 73 (47.1%) | 0.03 |
Glucose, mean±SD | 5.5 (1.5) | 5.2 (1.3) | 0.12 |
Anti-diabetes medications | 24 (11.8%) | 8 (5.2%) | 0.03 |
Impaired glucose tolerance | 63 (31%) | 32 (20.7%) | 0.02 |
Total cholesterol (mmol/l), mean±SD | 5 (1.1) | 5.2 (1.3) | 0.45 |
Triglycerides (mmol/l), mean±SD | 1.4 (0.9) | 1.5 (1.1) | 0.55 |
Abnormal triglycerides | 73 (36%) | 50 (32.3%) | 0.46 |
HDL (mmol/l), mean±SD | 1.4 (0.5) | 1.3 (0.4) | 0.69 |
Abnormal HDL | 50 (24.6%) | 43 (27.7%) | 0.51 |
LDL (mmol/l), mean±SD | 3 (0.9) | 3.1 (0.9) | 0.52 |
Lipid-lowering medications | 37 (18.2%) | 20 (12.9%) | 0.17 |
BMI (kg/m2), mean±SD | 29.5 (6.6) | 28.2 (5.5) | 0.05 |
BMI>30 | 81 (40.7%) | 45 (29.8%) | 0.04 |
Abdominal obesity* | 101 (50.3%) | 65 (41.9%) | 0.12 |
hsCRP (mg/l), mean±SD | 12.3 (24.4) | 4.3 (13.1) | <0.001 |
NSAID, current use | 121 (59.6%) | 10 (6.5%) | <0.001 |
DMARD, current use | 117 (57.6%) | 18 (11.6%) | <0.001 |
Anti-TNFα agents, current use | 82 (40.4%) | 11 (7.1%) | <0.001 |
Prednisone, current use | 7 (3.4%) | 0 | 0.02 |
*Waist circumference ≥88 cm for women and ≥102 for men.
BMI, body mass index; DBP, diastolic blood pressure; DMARD, disease-modifying antirheumatic drug; HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; PsC, cutaneous psoriasis without arthritis; SBP, systolic blood pressure; TNFα, tumour necrosis factor α.